Compare Rigetti Computing Inc (RGTI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs Twist Bioscience Corp — how do they compare? Rigetti Computing Inc trades at $15.2 (market cap $5.28B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| RGTI | TWST | |
|---|---|---|
Market Cap | $5.28B | $8.42B |
Sector | Technology | Health |
52-Week High | $56.34 | $153.10 |
52-Week Low | $12.90 | $24.16 |
Enterprise Value | $4.89B | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rigetti Computing (RGTI) trades at $15.81, up 4.01% today, amid mixed signals with bearish technical indicators but strong analyst support. The stock shows significant fundamental challenges with a P/S ratio of 391.11 and deeply negative profit margins (-1,787.4% net income margin), though recent government funding of $100 million provides crucial support. Technical analysis indicates bearish momentum with support at $15 and resistance at $17.
The outlook remains speculative with substantial execution risks and widening losses, offset by government backing and quantum computing potential. Investment opportunity hinges on long-term technology commercialization, while immediate risks include persistent cash burn and competitive pressures in the nascent quantum sector.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
